Information Provided By:
Fly News Breaks for January 21, 2016
ALKS
Jan 21, 2016 | 11:25 EDT
Jefferies analyst Biren Amin cut his price target for Alkermes to $58 after removing ALKS 5461 revenue estimates from his model following the two Phase 3 trial failures. The path forward for the investigational depression treatment is "treacherous," Amin tells investors in a research note. The analyst keeps a Buy rating on Alkermes.
News For ALKS From the Last 2 Days
There are no results for your query ALKS